title: Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: results of the French CANDIDOSCOPE study.
abstract: OBJECTIVE
  The aim of this pharmaco-epidemiological study was to evaluate the prevalence of oropharyngeal candidiasis (OPC) in cancer patients treated with chemotherapy and/or radiotherapy.
  
  
  METHODS
  Signs and symptoms of OPC were noted for all patients. Antifungal therapeutic management was recorded in OPC patients. Patients receiving local antifungal treatments were monitored until the end of treatment.
  
  
  RESULTS
  Enrolled in the study were 2,042 patients with solid tumor and/or lymphoma treated with chemotherapy and/or another systemic cancer treatment and/or radiotherapy. The overall prevalence of OPC was 9.6% (95% confidence interval, 8.4%-11.0%] in this population. It was most frequent in patients treated with combined chemoradiotherapy (22.0%) or with more than two cytotoxic agents (16.9%). Local antifungal treatments were prescribed in 75.0% of OPC patients as recommended by guidelines. The compliance to treatment was higher in patients receiving once-daily miconazole mucoadhesive buccal tablet (MBT; 88.2%) than in those treated with several daily mouthwashes of amphotericin B (40%) or nystatin (18.8%).
  
  
  CONCLUSIONS
  OPC prevalence in treated cancer patients was high. Local treatments were usually prescribed as per guidelines. Compliance to local treatments was better with once-daily drugs.
authors.affiliation: APHP Tenon, APREC, University Paris VI, Paris, France.
authors.forename: Joseph
authors.initials: J
authors.lastname: Gligorov
authors.forename: Laurent
authors.initials: L
authors.lastname: Bastit
authors.forename: Honorine
authors.initials: H
authors.lastname: Gervais
authors.forename: Mehdi
authors.initials: M
authors.lastname: Henni
authors.forename: Widad
authors.initials: W
authors.lastname: Kahila
authors.forename: Daniel
authors.initials: D
authors.lastname: Lepille
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Luporsi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Sasso
authors.forename: Charles
authors.initials: C
authors.lastname: Varette
authors.forename: David
authors.initials: D
authors.lastname: Azria
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology; D002180:Candidiasis, Oral / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009960:Oropharynx / Q000382:microbiology; D010608:Pharyngeal Diseases / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B